Search
Rasagiline
go.drugbank.com/drugs/DB01367ApprovedInvestigationalRasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Cytochrome P-450 SubstratesProducts: ETKINIA 1 MG TABLET, 100 ADET, NOPARKS 1 MG TABLET ,100 TABLETMefenamic acid
go.drugbank.com/drugs/DB00784ApprovedA non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.
Mixtures: แอนพัส 520Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsSimvastatin
go.drugbank.com/drugs/DB00641ApprovedInvestigational[A181087, A181406] Evidence has shown that even for low-risk individuals (with <10% risk of a major vascular event occurring within 5 years) statins cause a 20%-22% relative reduction in major cardiovascular … [A181397, A181403] While all statin medications are considered equally effective from a clinical standpoint, [rosuvastatin] is considered the most potent; doses of 10 to 40mg [rosuvastatin] per day
Mixtures: SimEz 10 mg/10 mg Tabletten, Ezesim 10 mg/10 mg-TablettenCategories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesGalantamine
go.drugbank.com/drugs/DB00674ApprovedInvestigational[A182993] The drug was approved by the FDA in 2001 for the treatment of mild to moderate dementia of the Alzheimer's type. … [L13571] It is therefore not considered to be a disease-modifying drug.
Mixtures: GALNORA 8MG + 16MG HKP RET, GALNORA 8MG + 16MG HKP RETCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesUstekinumab
go.drugbank.com/drugs/DB05679ApprovedInvestigationalIn October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults. … [A187349] It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice.
Products: STELARA 130 MG, STELARA 130 MG / 26 ML İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRETamoxifen
go.drugbank.com/drugs/DB00675ApprovedInvestigationalTamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. … [A1026] Tamoxifen was granted FDA approval on 30 December 1977.[L7799]
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesProducts: TAMOXIT 10 MG FİLM KAPLI TABLET (TAMOFEN), 100 TABLET, NOVOFEN (10 MG)Dabrafenib
go.drugbank.com/drugs/DB08912ApprovedInvestigational[L41955] In May 2018, Tafinlar (dabrafenib), in combination with Mekinist ([DB08911]), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.[L41955]
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesProducts: TAFINLAR 75 MG KAPSÜL ,120 ADET, TAFINLAR (CAPSULES 50 MG)Denosumab
go.drugbank.com/drugs/DB06643ApprovedInvestigationalIt is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss. … Two denosumab biosimilars—Wyost® (denosumab-bbdz) [L53063] and Jubbonti® (denosumab-bbdz)[L53058]—were approved by the FDA in March 2024 for all indications of the reference products Xgeva® and Prolia®
Products: XGEVA® 120 MG/1.7 ML, XGEVA Solution for Injection 120 mg/vialTretinoin
go.drugbank.com/drugs/DB00755ApprovedInvestigationalNutraceutical[A257689] It has been used in dermatology for many years to treat various skin conditions ranging from acne to wrinkles [A257474,A258185] and activates nuclear receptors to regulate epithelial cell growth … [A257474,A257629,A257609] Tretinoin is given orally to treat acute promyelocytic leukemia [L45349] and topically to treat skin conditions such as acne.[L45389,L34869,L45384]
Synonyms: Tretin MMixtures: Acnatac 10 mg/g + 0,25 mg/g Gel, CLİNDATRE 12 MG/G + 0,25 MG/G JEL, 30 GRAMDicyclomine
go.drugbank.com/drugs/DB00804ApprovedInvestigationalDicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder … [A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may have been based on a small amount of evidence and so its prescription is becoming less favourable.
Mixtures: แอนพัส 520Products: RELESTAL PEDIATRIC SYRUP 10 mg/5 ml, Bentylol Inj 10mg/ml